世界*实验材料供应商 Pranovo Biotech上海金畔生物为其中国代理， Pranovo Biotech在一直是行业的*,一直为广大科研客户提供zui为的产品和服务,上海金畔生物一直秉承为中国科研客户带来的产品，的服务， Pranovo Biotech就是为了给广大科研客户带来更加完善的产品和服务,您的满意将是我们zui大的收获
Pranovo Biotech中国代理, Pranovo Biotech上海代理，Pranovo Biotech 特约代理理，Pranovo Biotech广东代理， Pranovo Biotech江苏代理Pranovo Biotech湖北代理,Pranovo Biotech天津,Pranovo Biotech黑龙江代理,Pranovo Biotech内蒙古代理,Pranovo Biotech吉林代理,Pranovo Biotech福建代理, Pranovo Biotech江苏代理, Pranovo Biotech浙江代理, Pranovo Biotech四川代理,
Pranovo Biotech是一家不断发展的生物技术公司，我们主要生产高度纯化的重组蛋白/抗体，包括细胞因子，生长因子，趋化因子，激素，酶，病毒抗原和许多其他重组蛋白，用于癌细胞因子相关产品的研究团体，凋亡，内分泌学，免疫学，神经科学，蛋白酶和干细胞研究。
同时，我们提供广泛的分子生物学服务，包括定制肽服务，范围从抗原设计，固相合成，修饰和纯化; 客户抗体服务范围从重组蛋白表达，肽设计和合成，多克隆和单克隆抗体生产，表达多克隆和单克隆抗体生产，亲和纯化，共轭，分离和免疫测定开发。
制品：
-
- 重组蛋白
- 抗体
- 小鼠Mab抗体
- 兔Mab抗体
- 兔Pab抗体
- 标签抗体
- 二抗
- 对照抗体
- 色谱介质
- 酶和试剂盒
Cynomolgus BCA-1/ BLC/ CXCL13 Protein (His Tag)
Please Choose:Application
Antibody Production; ELISA; Protein Array; Western Blot;
Size 1mg
50μg
Cynomolgus BCA-1/ BLC/ CXCL13 Protein (His Tag)
For Research Use Only
Synonym :
BCA-1, BLC, CXCL13, C-X-C Motif Chemokine 13
Source:
Recombinant Cynomolgus BCA-1/ BLC/ CXCL13 Protein, Val 23 – Pro 109(NP_001028052.1) was expressed in E.coli cells.
Molecular Characterization:
Recombinant Cynomolgus BCA-1/ BLC/ CXCL13 Protein, with a 6*His tag at the N-terminus, consists of 103 amino acids and has a calculated molecular mass of 12.4 kDa. The apparent molecular mass of Recombinant Cynomolgus BCA-1/ BLC/ CXCL13 Protein is approximay 14 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Sequence:
Cynomolgus BCA-1/ BLC/ CXCL13 Protein (His Tag)
Endotoxin:
<1.0 EU per μg of the Recombinant Cynomolgus BCA-1/ BLC/ CXCL13 Protein by the LAL method.
Purity:
>90% as determined by SDS-PAGE.
SDS-PAGE:
Formulation:
Lyophilized from sterile 10 mM Tris, 250mM NaCl, pH 8.0
Normally 5 % – 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Contact us for customized product format or formulation.
Storage:
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
• 4-8℃ for 1 year in lyophilized state
• 4-8℃ for 1 month under sterile conditions after reconstitution
• -20℃ to -70℃ for 3 months under sterile conditions after reconstitution
Reconstitution:
Reconstitution instruction will be sent along with the products. Please refer to it for detailed information.
Background:
Cynomolgus CXCL13, also known as BCA-1 ( B-cell-attracting chemokine-1 ) or BLC ( B-lymphocyte chemoattractant ), is a major regulator of B-cell trafficking. BCA-1/ BLC/ CXCL13 Protein is a small cytokine belonging to the CXC chemokine family. BCA-1/ BLC/ CXCL13 and its receptor CXCR5 control the organization of B cells within follicles of lymphoid tissues. BCA-1/ BLC/ CXCL13 Protein is known to dictate homing and motility of B cells in lymphoid tissue and has been implicated in the formation of ectopic lymphoid tissue in chronic inflammation. The increased level of BCA-1/ BLC/ CXCL13 Protein is a feature of systemic lupus erythematosus (SLE) that correlates with disease activity. Furthermore, BCA-1/ BLC/ CXCL13 Protein might be a readily available surrogate marker to monitor the extent of aberrant B-cell (dys-)function. The vascular endothelial BCA-1/ BLC/ CXCL13 Protein expression may be consequent to transcytosis. In Primary central nervous system lymphoma (PCNSL), expression of BCA-1/ BLC/ CXCL13 Protein by malignant lymphocytes and vascular endothelium may influence tumor development and localization to central nervous system (CNS). BCA-1/ BLC/ CXCL13 Protein expression is a distinctive feature of angioimmunoblastic T-cell lymphoma, providing further support for the germinal center T-helper cell as the cell of origin for this neoplasm. Furthermore, BCA-1/ BLC/ CXCL13 Protein, a chemokine that may participate in tumor pathogenesis and is a potential target for novel therapies.
